Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

N. Girard,B. Besse,R. Bernabe Caro, K. Goto,N. Leighl,Y. Ohe,J. Sabari,S-H. Lee, X. Lin, M. Schaeffer,S. Nair, T. Li,L. Di Scala,R. Potluri,P. Mahadevia,M. Thayu,T. M. Kim

Journal of Thoracic Oncology（2022）

Cited 0|Views5

No score

Abstract

For patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC), osimertinib is recommended frontline therapy. However, real-world treatment patterns, clinical outcomes, healthcare-resource utilization (HRU), and costs in frontline and post-osimertinib settings are unclear.

Translated text

Key words

Real-world evidence, EGFR-mutant

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined